Optalert

Optalert developed the worlds leading algorithm to quantify the deterioration in cognitive brain function due to drowsiness and created the Johns Drowsiness Scale (JDS) which remains the only scientifically proven, objective measurement of drowsiness. The JDS is used worldwide in research for accurately quantifying drowsiness levels, and in Optalerts early-warning drowsiness detection systems to protect thousands of lives and valuable company assets across multiple industries. Our clients include BHP Billiton, Vale and NASA. Our research partners include the Harvard Medical School, Monash University, and the University of Queensland. Optalert is a Medical Technology company pioneering the use of Blepharometry (the...

Fatigue management,alertness monitoring,fatigue risk profiling,drowsiness detection,wearable technology,early warning drowsiness detection,data reporting,risk reduction from fatigue related accidents,licensing,pharmaceutical,epworth sleepiness scale,johns drowsiness scale,jds,ess,medical trials,machine learning,neurology,sleep,epilepsy,shiftwork,tbi,traumatic brain injury,wakefulness,automotive,inattention,oem,distraction,artificial intelegence,cns,central nervous system,sleepiness,clinical trials, neurotoxicity,murray johns,drowsy driving,microsleeps,fatigue,driver monitoring systems,ncap,euroncap,and biomarkers

Optalert operates in the Biotechnology industry.

Optalert's revenue is 1m - 10m

Optalert has 11 - 50 employees.